Viewmind
Viewmind is a digital health and AI company developing digital biomarkers for early detection of Alzheimer's disease and Mild Cognitive Impairment, serving healthcare providers, researchers, and pharma with AI-native cognitive assessment technology.
- Company typePrivate
- Founded2016
- HeadquartersAlpine, United States
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What Viewmind does
Viewmind is a digital health and artificial intelligence company developing digital biomarkers for the early detection of Alzheimer's disease and Mild Cognitive Impairment (MCI). Founded in 2016 and headquartered in Alpine, United States, the company is also identified as a Latin America-based AI startup, having been featured in Hi Ventures' AI 100 Early Stage Map 2025. Its core offering is an AI-driven cognitive assessment that detects neurodegenerative conditions at earlier stages than traditional diagnostic methods, positioning it at the intersection of AI-native diagnostics and the high-burden Alzheimer's care market. Target end users are not explicitly disclosed but likely include healthcare providers, neurology clinics, clinical researchers, and pharmaceutical companies engaged in Alzheimer's drug development and patient screening.
The company's product is built around proprietary AI models that analyze digital biomarker data to identify signatures of cognitive decline. As an AI-native diagnostic, the underlying technology constitutes the company's primary value proposition rather than serving as an add-on feature. Headcount remains small (1-10 employees), and no patents, regulatory clearances, or third-party clinical validation milestones are disclosed in available sources, leaving the depth of the AI capability largely self-asserted.
Viewmind's business model is not publicly disclosed. It has raised between $1M and $10M USD across multiple funding rounds between 2020 and 2023 (with only the 2020 Cites-led $1M round publicly confirmed), and recently hired its first dedicated commercial leader (VP of Sales & Business Development). The company appears to be in a pre-commercial or early-commercial phase, with revenue figures undisclosed and its public website showing only a verification page. The GTM motion and pricing model are therefore not yet observable.
Viewmind firmographics
Firmographics- Name
- Viewmind
- Website
- https://viewmind.ai
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Viewmind is a digital health and AI company developing digital biomarkers for early detection of Alzheimer's disease and Mild Cognitive Impairment, serving healthcare providers, researchers, and pharma with AI-native cognitive assessment technology.
- Ownership category
- akta.pro rank
Viewmind industry classification
Industry- Product category
- Digital Health Cognitive Diagnostics
- NAICS
- Software Publishers (5132), Software Publishers (513210)
- SIC
- Services-Prepackaged Software (7372)
- akta.pro primary industry
- SaMD – Digital Biomarkers & Algorithmic Endpoints (HLACANAF)
- akta.pro secondary industries
- SaMD – Imaging & Signal Analysis (AI/ML) (HLACANAG), Cognitive & Behavioral Neurology (Dementia/Memory Disorders) (HLAKAIAH), Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables) (HLAHACAE)
Keywords
Where Viewmind is headquartered
LocationHeadquarters
- HQ city
- Alpine
- HQ country
- United States
- HQ region
- North America
Markets served
Viewmind business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Marketing or Sales
Viewmind product offering
Product offeringCore offering
Viewmind develops and sells a digital biomarker that uses artificial intelligence to enable early detection of Alzheimer's disease and Mild Cognitive Impairment (MCI). The offering is a non-invasive cognitive screening software tool aimed at clinicians and clinical researchers seeking earlier identification of cognitive decline.
Differentiator
Problem solved
Functional benefit
Products and services
- Viewmind Digital Biomarker for Alzheimer's and MCI Detection
Companies that use Viewmind
Customer profileIdeal customer profiles1 record
Viewmind technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Viewmind partnerships and signals
Strategic signalRecent moves5 records
Expansion highlights4 records
Viewmind competitors and assessment
Company assessmentMarket position
Competitive moat4 records
Key risks6 records
Key highlights5 records
Customer concentration
Viewmind financial estimates
Financial estimateRevenue estimate
Valuation estimate
Viewmind leadership team
Management profileNumber of profiles
Profiles4 records
Viewmind funding detail
Funding detailFunding overview
Funding rounds3 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Viewmind M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Viewmind
What does Viewmind do?
Viewmind develops and sells a digital biomarker that uses artificial intelligence to enable early detection of Alzheimer's disease and Mild Cognitive Impairment (MCI). The offering is a non-invasive cognitive screening software tool aimed at clinicians and clinical researchers seeking earlier identification of cognitive decline.
Is Viewmind a public or private company?
Viewmind is a private company. It is classified as venture growth investor backed and is currently operating.
When was Viewmind founded?
Viewmind was founded in 2016. It employs 11 to 50 people.
Where is Viewmind based?
Viewmind is headquartered in Alpine, United States, in the North America region.
Does Viewmind have an API?
No public API is recorded for Viewmind.
What industry is Viewmind in?
Viewmind's product category is Digital Health Cognitive Diagnostics. Its primary akta.pro industry code is HLACANAF, SaMD – Digital Biomarkers & Algorithmic Endpoints, with a secondary code of HLACANAG, SaMD – Imaging & Signal Analysis (AI/ML). Its NAICS code is 5132 and its SIC code is 7372.